B. Conrad

发表

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.

A. Schneeweiss, R. Kreienberg, S. Loibl, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.

M. Rezai, T. Fehm, S. Loibl, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69

A. Schneeweiss, C. Denkert, S. Loibl, 2015 .

ZORO: A prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37).

S. Loibl, H. Sommer, B. Gerber, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*

U. Fuhr, S. Loibl, N. Harbeck, 2014, Breast Care.

Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial.

W. Eiermann, W. Jonat, G. von Minckwitz, 2004, Journal of Clinical Oncology.

Gain study: A phase III trial to compare ETC versus EC-TX and ibandronate versus observation in patients with node-positive primary breast cancer.

R. Kreienberg, H. Tesch, S. Loibl, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52)

C. Denkert, W. Eiermann, F. Marmé, 2015, Cancer.

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.

A. Schneeweiss, C. Denkert, S. Loibl, 2016, The Lancet. Oncology.

Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial.

P. Fasching, A. Schneeweiss, C. Denkert, 2018 .

A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93.

M. Schumacher, W. Eiermann, W. Jonat, 2007, European journal of cancer.

CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).

W. Eiermann, W. Jonat, G. von Minckwitz, 2006, European journal of cancer.

Goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with breast cancer. GABG trial IV-B-93

W. Eiermann, W. Jonat, G. Gademann, 2004 .

German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients

T. Fehm, A. Schneeweiss, H. Tesch, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)

S. Loibl, V. Nekljudova, G. Minckwitz, 2011, Supportive Care in Cancer.

Rare case of remission of a patient with small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) stage IV: Case report

D. Betticher, A. Feki, F. Khomsi, 2019, International journal of surgery case reports.

Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer

A. Hinke, G. Schaller, P. Klare, 2005 .

Goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with breast cancer. GABG trial IV-B-93.

W. Eiermann, W. Jonat, G. Gademann, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S2-4: GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer – 1st Interim Efficacy Analysis.

A. Schneeweiss, R. Kreienberg, S. Loibl, 2011 .

Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.

M. Schumacher, W. Eiermann, S. Loibl, 2010, European journal of cancer.

Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.

M. Schumacher, W. Eiermann, W. Jonat, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED)

A. Hauschild, D. Schadendorf, C. Garbe, 2019, Annals of Oncology.

Abstract S3-04: The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer

S. Loibl, M. Untch, V. Nekljudova, 2015 .

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

M. Rezai, T. Fehm, T. Kühn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.

M. Rezai, T. Fehm, S. Loibl, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.